{
    "2019-02-27": [
        [
            {
                "time": "2018-01-02",
                "original_text": "衡量公司真实盈利能力 净现比才是A股的“照妖镜”",
                "features": {
                    "keywords": [
                        "净现比",
                        "盈利能力",
                        "A股"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "2018年全球医疗机器人行业发展前景广阔 亚洲市场或将成为转移重心",
                "features": {
                    "keywords": [
                        "医疗机器人",
                        "亚洲市场",
                        "发展前景"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗设备"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "医药生物：首个国产生物类似药获批释放积极信号",
                "features": {
                    "keywords": [
                        "生物类似药",
                        "获批",
                        "医药生物"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "融资买入额激增 生物医药板块补涨",
                "features": {
                    "keywords": [
                        "融资买入额",
                        "生物医药",
                        "补涨"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "复星医药分拆复宏汉霖冲刺港股IPO 上市前夕首个国产生物类似药获批",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "港股IPO",
                        "生物类似药",
                        "获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "复星医药:中国首个生物类似药获批,验证公司研发实力",
                "features": {
                    "keywords": [
                        "复星医药",
                        "生物类似药",
                        "研发实力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}